Y-mAbs Therapeutics (NASDAQ:YMAB) Coverage Initiated by Analysts at Oppenheimer

Oppenheimer initiated coverage on shares of Y-mAbs Therapeutics (NASDAQ:YMAB - Free Report) in a research report sent to investors on Monday, Marketbeat.com reports. The firm issued an outperform rating and a $23.00 price target on the stock.

Other analysts have also issued reports about the stock. HC Wainwright restated a "buy" rating and set a $22.00 target price on shares of Y-mAbs Therapeutics in a research report on Friday. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $20.00 price objective on shares of Y-mAbs Therapeutics in a research note on Monday, September 9th. Wedbush reiterated an "outperform" rating and set a $23.00 price objective on shares of Y-mAbs Therapeutics in a research note on Tuesday, September 10th. Canaccord Genuity Group reaffirmed a "buy" rating and set a $26.00 price target on shares of Y-mAbs Therapeutics in a report on Tuesday, August 13th. Finally, Canaccord Genuity Group raised shares of Y-mAbs Therapeutics to a "strong-buy" rating in a research note on Tuesday, August 13th. One research analyst has rated the stock with a sell rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $21.38.

Y-mAbs Therapeutics Stock Performance

Shares of NASDAQ YMAB traded down $0.42 during midday trading on Monday, hitting $10.72. 328,069 shares of the stock traded hands, compared to its average volume of 331,540. The firm has a market capitalization of $480.14 million, a P/E ratio of -20.35 and a beta of 0.68. Y-mAbs Therapeutics has a one year low of $5.17 and a one year high of $20.90. The firm has a 50-day moving average of $13.98 and a two-hundred day moving average of $13.05.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last posted its earnings results on Friday, November 8th. The company reported ($0.16) earnings per share for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.02). The firm had revenue of $18.46 million during the quarter, compared to the consensus estimate of $23.38 million. Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. During the same period in the prior year, the company posted ($0.18) EPS. Equities analysts forecast that Y-mAbs Therapeutics will post -0.64 earnings per share for the current fiscal year.

Insider Activity at Y-mAbs Therapeutics

In other Y-mAbs Therapeutics news, insider Thomas Gad sold 65,000 shares of the company's stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $13.47, for a total transaction of $875,550.00. Following the sale, the insider now directly owns 97,681 shares in the company, valued at $1,315,763.07. This represents a 39.96 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, COO Joris Wilms sold 5,000 shares of the business's stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $14.69, for a total value of $73,450.00. Following the transaction, the chief operating officer now directly owns 30,600 shares in the company, valued at approximately $449,514. This represents a 14.04 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 100,000 shares of company stock valued at $1,338,100 over the last 90 days. 22.50% of the stock is owned by corporate insiders.

Institutional Trading of Y-mAbs Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Empire Financial Management Company LLC bought a new position in shares of Y-mAbs Therapeutics during the third quarter valued at approximately $210,000. Geode Capital Management LLC boosted its holdings in Y-mAbs Therapeutics by 6.2% during the 3rd quarter. Geode Capital Management LLC now owns 813,489 shares of the company's stock valued at $10,699,000 after acquiring an additional 47,846 shares during the period. Barclays PLC grew its position in Y-mAbs Therapeutics by 433.4% in the 3rd quarter. Barclays PLC now owns 69,222 shares of the company's stock valued at $910,000 after acquiring an additional 56,244 shares during the last quarter. State Street Corp grew its position in Y-mAbs Therapeutics by 50.4% in the 3rd quarter. State Street Corp now owns 1,209,781 shares of the company's stock valued at $15,909,000 after acquiring an additional 405,169 shares during the last quarter. Finally, Caligan Partners LP increased its stake in Y-mAbs Therapeutics by 105.3% in the third quarter. Caligan Partners LP now owns 1,195,253 shares of the company's stock worth $15,718,000 after purchasing an additional 613,175 shares during the period. 70.85% of the stock is owned by hedge funds and other institutional investors.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.